Beneficial effect of Raloxifene on high turn-over bone in chronic hemodialysis patients

INTERVENTION: medication of Raloxifene CONDITION: chronic kidney disease postmenopausal osteoporosis PRIMARY OUTCOME: serum bone alkaline phosphatase (BAP) level; serum bone‐specific tartrate‐resistant acid phosphatase (TRAP5b) level SECONDARY OUTCOME: serum levels od iPTH, calcium, phosphate, total cholesterol, and triacylglyceride INCLUSION CRITERIA: Postmenopausal hemodialysis patients of 50 years old or over with high serum alkaline phosphatase levels (>= 370 U/L), BAP levels (>= 35.4 U/L), or TRAP‐5b levels (>= 4.2 U/L).